The global oncology market faces the dual problem of increasing drug development expenses and the high failure rate of oncology drugs

The current ROI in drug development has been estimated to be as low as 0.3%. As experts try to reduce expenses and increase their chances of success, the industry is witnessing an increased emphasis on early decision making, adaptive programme design and strategic clinical alliances.

Over the 2 days, the Oncology Clinical Development Congress will provide a high-level platform for discussing these challenges and hearing case studies from those who have taken great steps in overcoming them.  The conference programme consists of 20 world-class keynote addresses, industry and academic led presentations and panel debates, creating an interactive forum for scientific and business debate.

Over the two days, key opinion leaders will explore pioneering solutions and critical opportunities in areas such as targeted therapeutics, clinical imaging and operations management. On Day 1, our internationally recognised experts will discuss strategies for co-developing combined therapies, establishing clear endpoints and building successful clinical partnerships. On Day 2, delegates will hear from those working at the forefront of trial design, patient selection and clinical outsourcing.

The event will be co-located with the 3rd Annual Oncology Biomarker’s Congress. This congress will bring together key scientists whose expertise is focused on biomarkers, companion diagnostics, personalized medicine, safety studies, translational medicine and decision making in the oncology therapeutic area, from leading pharmaceutical, biotechnology, diagnostics, clinical research companies and academic institutions in the UK and Europe.

For more information click here